Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis

Phase 2

Completed

• Conditions: Osteoporosis
• Interventions: Drug: Alendronate

• Registration Number: NCT00259857
• Lead Sponsor: Medical University of South Carolina

Brief Summary

We have previously evaluated the safety and efficacy of Alendronate in 10 patients with juvenile osteoporosis during a 12-month clinical trial. We have documented that Alendronate improved BMD of the spine and hip without any major side effects. There were no additional fractures during therapy. The present study is designed to further evaluate the safety and efficacy of Alendronate in 20 children with juvenile osteoporosis using a double-blind, randomized, placebo-controlled, cross-over protocol.

Detailed Description

Osteoporosis is an uncommon disease in children and early adolescents. Patients have a low bone mineral density, develop fractures with minimal or no trauma, and frequently have a negative family history. The disease results from either diminished bone formation or increased bone removal (resorption). No specific drug therapy has been recommended for juvenile osteoporosis. Alendronate (Fosamax) is effective in inhibiting bone resorption, increasing BMD and reducing fractures in adults with postmenopausal osteoporosis, but have not become established therapies in children. In the present study, we plan to evaluate the safety and efficacy of Alendronate in 20 patients with juvenile osteoporosis in a two-year period. This is a randomized, double-blind, placebo-controlled protocol. In the year-1, 10 patients will be assigned to receive Alendronate and 10 patients placebo. In the year-2, patients will be crossed over to the second arm of the study. Those who received Alendronate in the year-1, will receive placebo in the second year and vice verse. The patients will have 5 visits, the initial screening visit followed by 4 post therapy visits in a six-month interval. Measurements include DXA bone density scan of spine and hip, urinalysis and blood work.

Study Timeline

• Study Start: 2003-10
• Study First Submitted: 2005-11-29
• Study First Submitted QC: 2005-11-29
• Study First Posted: 2005-12-01
• Primary Completion: 2008-03
• Study Completion: 2009-08
• Results First Submitted: 2010-11-09
• Status Verified: 2010-12
• Results First Submitted QC: 2010-12-29
• Last Update Submitted: 2010-12-29
• Results First Posted: 2011-01-19
• Last Update Posted: 2011-01-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• Male and female children with a history of one or more atraumatic fractures, or evidence of one or more compression fractures on radiographs of the spine (reduction of >20 percent).
• Bone Mineral Density (BMD) determined by DXA sacn to confirm osteoporosis at a Z score greater than 2 SD (standard deviations) below the normal mean for age (Z score < -2 SD).
• Parental consent (and patient assent after age 12 years) to participate in the study.
• Sexual development at: Tanner stage II or less (Prepubertal stage).
• Weight = 20 kg and more.

Read More

Exclusion Criteria

• History of severe gastritis or reflux.
• Abnormalities of the esophagus that delay emptying, such as strictures or achalasia
• Marked kyphoscoliosis or the inability to sit or stand for at least 30 minutes
• Hypersensitivity to bisphosphonates
• Uncorrected hypocalcemia
• History of gastric or duodenal ulcers
• Renal dysfunction as indicated by serum Cr >1.5 mg/dl.
• Liver dysfunction as indicated by serum SGPT > 2 times the upper limit for age or serum total bilirubin > 2.0 mg/dl.
• Diagnosis of osteogenesis imperfecta, a family history of osteogenesis imperfecta, blue sclerae or deafness.
• Diagnosis of active rickets or osteomalacia or serum bone alkaline phosphatase 2 times greater than normal for age.
• Pregnancy
• Anorexia Nervosa

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
1 Alendronate, Calcium, Vitamin D	Alendronate	Crossover study. Year-1, 10 participants will take study medication, calcium and vitamin D supplements and other 10 participants will take placebo, calcium and vitamin D supplements. Year-2, they will crossover to the second arm of the study. Those who took study medication and supplements in year-1, will take placebo and supplements in the year-2, and those 10 participants who took placebo and supplements in the year-1, will take study medications and supplements in the year-2.
2 Placebo, Calcium and Vitamin D	Alendronate	Year-1, 10 participants will take Alendronate (study medication)and calcium and vitamin D supplement). Another 10 participants will take placebo, calcium and vitamin D. In year-2 they will crossover. Those who took alendronate in the first year, will take Placebo, calcium and vitamin D for 12 months and those who took Placebo in the first year, will take Alendronate, calcium and vitamin D in the second year (12 months).

Primary Outcome Measures

Name	Time	Method
Number of Participants With Improvement in Bone Mineral Density (BMD) of Spine After Therapy	24 months therapy	BMD of lumbar spine was measured using DXA scan at visit 24 months (Year-2)after alendronate or placebo treatment.

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Improvement in Bone Mineral Density (BMD) of Hip After Therapy	12 months of therapy
Number of Participants With Improvement in BMD of Hip	24 months of therapy	Analysis was done per protocol and intention to treat.
Participants With Atraumatic Fractures	24 months	Number of participants with fractures at the completion of therapy.

Trial Locations

Locations (1)

Medical University of South Carolina; 🇺🇸 Charleston, South Carolina, United States